## Edgar Filing: Loxo Oncology, Inc. - Form 4

Loxo Onco Form 4 June 13, 20										
Check ti if no lor subject Section Form 4 Form 5 obligati may co <i>See</i> Inst 1(b).	<b>M</b> 4 UNITED this box nger to 16. or STATEN 5 Filed pu Section 17	MENT OF ( rsuant to Se (a) of the Pu	Washi CHANG S ction 16(a ıblic Utili	<b>ES IN</b> ECUE a) of th ty Hol	, D.C. 20 BENEF RITIES le Securi ding Con	<b>)549</b> ICIAL O <sup>V</sup> ties Excha	E COMMISSIO WNERSHIP OI nge Act of 1934, of 1935 or Secti 940	N OMB Number: Expires: Estimated burden hou response.	urs per	
(Print or Type	Responses)									
1. Name and Address of Reporting Person <u>*</u> Naider Avi Z.			2. Issuer Na Symbol	ame <b>an</b> o	l Ticker or	Trading	5. Relationship of Reporting Person(s) to Issuer			
			Loxo Onco	ology,	Inc. [LC	XO]	(Check all applicable)			
(Last) (First) (Middle) C/O LOXO ONCOLOGY, INC., 281 TRESSER BLVD, 9TH FLOOR			3. Date of Earliest Transaction (Month/Day/Year) 06/10/2016				X_ Director 10% Owner Officer (give titleOther (specify below) below)			
Filed			If Amendment, Date Original			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting				
STAMFO	RD, CT 06901						Person	whole than one R	eporting	
(City)	(State)	(Zip)	Table I	- Non-l	Derivative	Securities A	Acquired, Disposed	of, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Da any (Month/Day/	ate, if Tra Co /Year) (In	de str. 8)	4. Securit nAcquired Disposed (Instr. 3,	(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Reminder: Re	eport on a separate lin	e for each class			ficially ow Perso inforr requi	ned directly ons who rest nation contred to response	or indirectly. spond to the colle tained in this form ond unless the fo ntly valid OMB co	n are not orm	SEC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number	6. Date Exercisable and	7. Title and Amount of	8. I
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transactio	onof Derivative	Expiration Date	Underlying Securities	Der
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)	Sec

number.

## Edgar Filing: Loxo Oncology, Inc. - Form 4

(Instr. 3)	Price of Derivative Security	(	(Month/Day/Year)	(Instr.	8)	Acquire (A) or Dispose (D) (Instr. 3 and 5)	d of					(
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Director Stock Option (right to buy)	\$ 24.18	06/10/2016		A		7,812		<u>(1)</u>	06/09/2026	Common Stock	7,812	

## **Reporting Owners**

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
Naider Avi Z. C/O LOXO ONCOLOGY, INC. 281 TRESSER BLVD, 9TH FLOOR STAMFORD, CT 06901	Х					
Signatures						
/s/ Sara Slifka, by power of attorney	06/13	/2016				
**Signature of Reporting Person	Da	te				

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The stock option vests and becomes exercisable in 12 equal monthly installments beginning one month after the grant date, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

(In